2024 WCLC丨口头报告专场重磅研究一览：非小细胞肺癌

英文标题：Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC

中文标题：KEYNOTE-671研究：帕博利珠单抗用于早期NSCLC围手术期病理消退与EFS的关联

摘要号：OA01.03

讲者：D.R. Jones

英文标题：A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer

中文标题：可切除NSCLC围手术期接受依沃西单抗单药或联合化疗的II期研究

摘要号：OA01.04

讲者：X. Zhao

英文标题：The Effect of Personalized Music Therapy on Perioperative Pain and Anxiety in NSCLC Patients

中文标题：个性化音乐疗法对NSCLC患者围手术期疼痛和焦虑的影响

摘要号：OA07.03

讲者：Y. Yuan

英文标题：ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)

中文标题：ALINA研究安全性结果：阿来替尼 vs. 化疗辅助治疗切除的ALK阳性NSCLC患者

摘要号：OA13.03

讲者：H. Horinouchi

英文标题：I-SABR-SELECT: A Radiomics-Based Model for Personalized Immunotherapy for Early-Stage Non-Small Cell Lung Cancer

中文标题：I-SABR-SELECT研究：基于放射组学的早期NSCLC个性化免疫治疗模型

摘要号：OA13.04

讲者：M.B. Saad

英文标题：A Phase III Study of Rilertinib Versus Gefitinib as First-Line Therapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC

中文标题：瑞厄替尼 vs. 吉非替尼作为局晚期或转移性EGFR突变非小细胞肺癌（NSCLC）患者一线治疗的III期研究

摘要号：OA02.03

讲者：A. Xiong

英文标题：Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA

中文标题：MARIPOSA研究：Lazertinib vs. 奥希替尼一线治疗EGFR突变晚期NSCLC

摘要号：OA02.04

讲者：S-H. Lee - h

英文标题：KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study

中文标题：KRAS G12C抑制剂IBI351治疗晚期NSCLC患者的关键II期研究更新结果

摘要号：OA14.03

讲者：Q. Zhou

英文标题：Telisotuzumab Vedotin in Asian Patients with C-Met Protein-Overexpressing Non-Squamous EGFR WT NSCLC: Results from LUMINOSITY

中文标题：LUMINOSITY研究：Telisotuzumab Vedotin治疗C-Met蛋白过表达非鳞状EGFR WT NSCLC亚洲患者

摘要号：OA16.03

讲者：H. Horinouchi

英文标题：Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-Averexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1

中文标题：TINY-Lung03研究第1部分：德曲妥珠单抗单药治疗经治HER-2过表达非鳞状NSCLC

摘要号：OA16.04

讲者：D. Planchard

英文标题：Preliminary Results from a FIH Study of GQ1005, A Novel HER2-ADC, in Patients with Advanced HER2-Expressing Solid Tumors and HER2-Mutated NSCLC

中文标题：FIH研究的初步结果：新型HER-2-ADC GQ1005治疗晚期表达HER-2的实体瘤和HER-2突变NSCLC患者

摘要号：OA16.05

讲者：C. Zhou

英文标题：Predicting Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced NSCLC with Machine Learning and CT Radiomics

中文标题：通过机器学习和CT放射组学预测晚期NSCLC患者接受帕博利珠单抗单药治疗后的疾病进展

摘要号：OA03.03

讲者：C. MacAulay c

英文标题：Ablation to Oligo-Residual Sites Plus ICIs Improved Survival of Patients with Advanced NSCLC: Preliminary Results of a Prospective Phase II Trial

中文标题：寡残留部位消融联合免疫检查点抑制剂可提高晚期NSCLC患者的生存率：一项前瞻性II期试验的初步结果

摘要号：OA05.03

讲者：S. Yang